Transgenic RPE cells overexpressing OTX2 for the treatment of retinal degeneration
US11865189B2 · kind B2 · utility
0Cited by
0References
18Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Dec 17, 2015 |
| Grant date | Jan 9, 2024 |
| Priority date | — |
| Expiry date | Dec 17, 2035 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2750/14141
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to methods and composition for use in the treatment of retinal degeneration, in particular retinal degeneration due to retinal pigment epithelium dysfunction.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.